Title of Project

Exploratory Research of Synergistic Pharmacokinetics of Artemisinin and Chloroquine in Equine Erythrocytes by High Pressure Liquid Chromatography (HPLC) with Ultraviolet and Fluorescence Detection

Researcher Information

Sachin R. Patel
Micheline D. Moini

Project Type

Event

Start Date

2010 12:00 AM

End Date

2010 12:00 AM

This document is currently not available here.

Share

COinS
 
Jan 1st, 12:00 AM Jan 1st, 12:00 AM

Exploratory Research of Synergistic Pharmacokinetics of Artemisinin and Chloroquine in Equine Erythrocytes by High Pressure Liquid Chromatography (HPLC) with Ultraviolet and Fluorescence Detection

Artemisinins form the most important class of antimalarial available, particularly because they have higher efficacy rate, act more rapidly, act on a broader base and act on resistant malaria by inhibiting major metabolic processes such as glycolysis, nucleic acid, and protein synthesis. Currently available artemisinin-based combination therapies (ACTs) for malaria are inadequate. There remains an enormous unmet need for alternate Anemisinin-based combination therapies. One of the fastest methods to identify promising Artemisinin-based combination therapies is to look for synergistic or additive antimalarial interactions between the endoperoxide artemisinin (a ses-quiterpenoid lactone peroxide) and alternate drugs such as Chloroquine (quinoline). They are directed against P. falciparum in vitro in equine erythrocytes. The project design was seeking to elucidate any possible interplay at the molecular level of erythrocytes between these classes of drugs. Previous publications in scientific literature show different mechanisms of action of the quinoline family and ACTs via RSAII protein transporter and DIO protein exchange. Results showed a strong indication of Chloroquine in HPLC Automated Analysis at 13.2 minutes and further comparison of the Patient C CQ and ART Trials with the Patient C Negative Control points to a possible artemisinin derivative peak between 8.3-8.6 minutes. Percent significance produced and standard deviation showed a 1.2% deviation upon Patient C trials.